S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Salt Lake Magazine Names Dr. Kian Eftekhari a 2026 Top Doctor

Peer-reviewed recognition from Salt Lake Magazine has named Dr. Kian Eftekhari, founder of the Eyelid Center of Utah, a 2026 Top Doctor. The award honors his surgical expertise in the oculofacial region, a specialized field covering the eyelids, tear system, and surrounding facial structures across the Wasatch Front.

Salt Lake Magazine Names Dr. Kian Eftekhari a 2026 Top Doctor
Photo: Bio & News

The selection process, managed by Professional Research Services, relies exclusively on nominations from licensed physicians practicing in the region. Voters choose peers they would trust with their own care or that of a family member, with winners subject to rigorous license verification. Dr. Eftekhari, a board-certified ophthalmologist, established his practice in 2019 following an academic tenure at the University of North Carolina at Chapel Hill.

His clinical focus blends reconstructive work with aesthetic procedures, including endoscopic forehead lifts and minimally invasive ptosis repair. Eftekhari emphasizes that his surgical philosophy prioritizes small incisions to reduce recovery time while maintaining natural facial character. Beyond his private practice in Salt Lake City, Draper, and Heber City, he contributes to the field through peer-reviewed research and national lectures, having previously received the Outstanding Contribution Award from the American Society of Ophthalmic Plastic and Reconstructive Surgery.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!